Spotlight on Trials

Spotlight on Trials

Enabling and funding research is just one of the ways we’re here, at every step, to support you with and beyond cancer.

For any enquiries regarding any of the trails please email: [email protected]

Could taking aspirin help reduce the chances of developing cancer?

January 2020
Weston Park’s participation in the international Add Aspirin trial hopes to determine whether or not aspirin, a common painkiller drug, could help reduce the chances of developing cancer. There is evidence that taking regular aspirin may reduce cancer diagnoses and their outcome but due to side effects which can be associated with taking aspirin on a regular basis, it is not yet clear whether the potential benefits outweigh the risks.
The trial which is being led by MRC Clinical Trials Unit at University College London is still recruiting patients with breast, prostate, bowel and oeosophagogastric cancers. So far 90 patients in Sheffield have participated, making a really valuable contribution to answering this important question.


“Pancreatic cancer survival rates haven’t improved in 50 years…we’re changing that”

November 2019  


This year, over £340,000 of our funds have been invested into Weston Park’s Cancer Clinical Trials Centre, which delivers the vital research and clinical trials that often change and save lives. This month, we’re catching up with Jon Wadsley who is leading trials on pancreatic cancer, currently the third leading cause of cancer death in the UK.


“We’re seeing pancreatic cancer become more prevalent, and it’s expected to become the 2ndleading cause of cancer death in the next decade.


From laboratory research we do now have a better understanding of the molecular changes underlying pancreatic cancer, and the fact that a number of subtypes of pancreatic cancer can be identified which might benefit from different, more targeted treatment. This may mean that we could potentially impact survival rates.


We’re inviting newly diagnosed patients to consent to a trial that involves taking some cancer tissue for molecular profiling. The data we gather is shared across a national database contributing to the same trial. That data, from across the UK, can help us to identify potentially more individualised treatment types, ones that patients of these specific cancers might respond better to. In time, I expect to see it change the way we treat and the patients live with and survive pancreatic cancer.”


Sheffield is one of a number of UK centres recruiting to this study, which fits perfectly with our goal at Weston Park Cancer Centre of increasingly personalising the treatment that we offer to our patients to ensure the best possible outcomes.